RxDoctor Payments Data

Cenk Ayata, MD

Neurology · Boston, MANPI 1326038043

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $4,680 of the $4,680 with a category attached, or 100.0%. Every reported general payment came from a single manufacturer, Neurelis, Inc..

$4,680in general payments, 2019–2025

Across 1 payment — averaging $4680.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurelis, Inc.$5K
$411,762in research payments, 2019–2025

Across 9 payments — averaging $45,751 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Takeda Pharmaceuticals U.S.A., Inc.$277K
  • Neurelis, Inc.$134K

What the payments were for

  • Consulting fees$4,680100%

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Neurelis, Inc.1$4,680

How this compares

$4,680 in reported general payments places this provider in the 70th percentile of 761 neurology providers in Massachusetts.

See all neurology providers in Massachusetts →

Medicare billing

Part B allowed, 2024
$21,249
Medicare patients
105
Services billed
128

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other neurology in Boston

See the full list for Massachusetts →

Where these figures come from

Is this you, or does something look wrong? →